Abstract 1814
Background
Tumor Treating Fields (TTFields) are intermediate frequency, alternating electric fields that non-invasively treat cancer. Transducer arrays positioned on the skin in proximity to the targeted tumor transmit TTFields. A post-hoc analysis [Ballo et al. Red Jour. 2019 In Press] has shown that increased patient usage (percent of time on active treatment) and intensity of TTFields delivery direct to the tumor improved survival. Optimal array positioning may enhance TTFields intensity at the tumor site to improve patient experience and survival. Minimization of array exposure area would enhance patient comfort levels and usage to improve survival. Optimizing TTFields delivery and distribution depends on array positioning and geometry, patient anatomy, and the heterogeneous electrical properties of different tissues. We present methodology to optimize TTFields delivery using numerical simulations.
Methods
TTFields delivery to the brain, lung, and abdomen utilizing representative computational models was investigated. The effects of transducer array size and position on field distribution within the phantoms was analyzed, and an approach to optimize TTFields delivery was developed.
Results
Field intensity was typically the greatest in between arrays, with larger arrays transmitting higher field power. Anatomical features, such as bones (spine) or a resection cavity significantly influenced field intensity within this region. A generalized methodology to optimize TTFields delivery for improved patient care was based on: (1) Striking a balance between maximal field intensity (largest arrays feasible) and minimal skin exposure to arrays in the disease area; (2) Positioning virtual arrays on a representative, computational patient model to test tumor localization between arrays, to simulate TTFields delivery to patient, and to assess optimal delivery; and (3) Applying an iterative algorithm to shift arrays around their initial positions until field intensity is maximized directly to the tumor bed.
Conclusions
A generalized treatment methodology as presented by these data will optimize TTFields delivery to the tumor site. Effective TTFields treatment planning is expected to improve patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novocure.
Funding
Novocure.
Disclosure
N. Urman: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. Z. Bomzon: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. H.S. Hershkovich: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. E.D. Kirson: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. A. Naveh: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. R. Shamir: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. E. Fedorov: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. C. Wenger: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure. U. Weinberg: Full / Part-time employment: Novocure; Shareholder / Stockholder / Stock options: Novocure.
Resources from the same session
5071 - Expression of estrogen receptor and programmed cell death-ligand 1 can be complementary prognostic factors in HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Soohyeon Kwon
Session: Poster Display session 3
Resources:
Abstract
5306 - Real-world data of clinicopathologic characteristics of young oropharyngeal cancer patients.
Presenter: Maria Nieva
Session: Poster Display session 3
Resources:
Abstract
3407 - The clinical significance and biological mechanisms of miR-499a in high-tobacco exposed head and neck squamous cell carcinoma
Presenter: Shiqi Gong
Session: Poster Display session 3
Resources:
Abstract
3310 - Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic squamous cell carcinoma of the head and neck
Presenter: Rachel Galot
Session: Poster Display session 3
Resources:
Abstract
2362 - Blood-based testing of mutations in patients with Head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Presenter: Florentia Fostira
Session: Poster Display session 3
Resources:
Abstract
4533 - The head and neck Lung Immune Prognostic Index (HN-LIPI): a prognostic Score for Immune Checkpoint Inhibitors (ICI) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) patients.
Presenter: Ruth Gabriela Herrera Gomez
Session: Poster Display session 3
Resources:
Abstract
5262 - Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI)
Presenter: Neus Baste Rotllan
Session: Poster Display session 3
Resources:
Abstract
3725 - Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Presenter: Jack Bui
Session: Poster Display session 3
Resources:
Abstract
2533 - A nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI).
Presenter: Luay Mousa
Session: Poster Display session 3
Resources:
Abstract
2929 - Changes of the Commensal Microbiome during Treatment are Associated with Clinical Response in the Nasopharyngeal Carcinoma Patients
Presenter: Tingting Huang
Session: Poster Display session 3
Resources:
Abstract